An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2024

Conditions
Myelofibrosis
Interventions
DRUG

KRT-232

administered by mouth

DRUG

Ruxolitinib

administered by mouth

Trial Locations (38)

1431

RECRUITING

Saint Ivan Rilski Hospital, Sofia

RECRUITING

University Mutiprofile Hospital Alexandrovska, Sofia

6120

RECRUITING

Department für Innere Medizin Universitätsklinik und Poliklinik für Innere Medizin IV Hämatologie/Onkologie, Halle

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

13009

RECRUITING

Institut Paoli-Calmettes, Marseille

14033

RECRUITING

CHU de Caen, Caen

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

21100

RECRUITING

Ospedale di Circolo e Fondazione MacchiASST Sette Laghi, Varese

21205

RECRUITING

John Hopkins University, Baltimore

29010

RECRUITING

Hospital Virgen de la Victoria, Málaga

34295

RECRUITING

CHU Saint Eloi, Montpellier

44106

RECRUITING

Cleveland Clinic, Cleveland

47014

RECRUITING

Istituto Tumori della Romagna (IRST), Meldola

48109

RECRUITING

University of Michigan, Ann Arbor

49933

RECRUITING

Chu Angers, Angers

50012

RECRUITING

Hospital de Dia Quiron Zaragoza, Zaragoza

50134

RECRUITING

University of Florence, Florence

52074

RECRUITING

Universitätsklinikum Aachen Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen

55131

RECRUITING

UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz III. Med. Klinik und Poliklinik, Mainz

72000

RECRUITING

Centre Hospitalier du Mans, Le Mans

73557

RECRUITING

Stauferklinikum Schwäbisch Gmünd, Mutlangen

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

95124

RECRUITING

Universita degli Studi di Catania, Catania

98109

RECRUITING

Fred Hutchinson Cancer Research Center, Seattle

340136

RECRUITING

Bologna University Hospital, Institute of Hematology, Bologna

7033001

RECRUITING

Shamir Medical Center ( Assaf Harofeh), Ẕerifin

Unknown

RECRUITING

Royal Adelaide Hospital, Adelaide

RECRUITING

Dr. Georgi Stranski, Pleven

RECRUITING

Hopital Saint Louis, Paris

RECRUITING

CHU Tours - Hôpital Bretonneau, Tours

RECRUITING

Universitaetsklinikum Jena, Jena

RECRUITING

Oddział Kliniczny Hematologii Szpitala Uniwersyteckiego w Krakowie, Krakow

RECRUITING

Szpital Wojewódzki w Opolu Sp zooOddzial Kliniczny Hematologii, Opole

RECRUITING

Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria

RECRUITING

Hospital Universitario de Salamanca, Salamanca

08035

RECRUITING

d'Hebron University Hospital in Barcelona, Barcelona

08916

RECRUITING

Hospital Universitario Germans Trias i Pujol, Barcelona

Sponsors
All Listed Sponsors
lead

Kartos Therapeutics, Inc.

INDUSTRY

NCT04485260 - An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | Biotech Hunter | Biotech Hunter